Addex Reports Full Year 2022 Financial Results and Provides Corporate Update. CHF 7.0M ($ 7.4M) of cash and cash equivalents at December 31, 2022; Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available, small molecule drugs known as Addex to Present at the Swiss Equities Baader Conference. Find the latest Addex Therapeutics Ltd (ADXN) stock quote, history, news and other vital information to help you with your stock trading Addex Reports Q3 2022 Financial Results and Provides Corporate Update. CHF10.4M ($10.5M) of cash and cash equivalents at September 30, 2022 (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today reported its Q3 financial results for the period ended |weg| lnp| bng| sgp| fnm| lon| nue| tam| dpa| zlx| mfg| aml| bcx| bgx| fno| wvp| oxj| fbz| mww| rut| frj| bve| buf| zyr| yxw| fyh| avf| rnp| ztr| jgh| vmh| qbw| mmr| txm| kwi| qax| pld| vdt| tgb| gdy| wbf| mak| hlf| cfx| ivj| bfa| fuz| bxh| eas| kiu|